A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
← catalyst calendarNCT06203210 · readout in 529 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
540estimated
Sites
229
Countries
Australia, Austria, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-21 | actual | When the study began enrolling |
| Primary completion | 2028-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer
Interventions
- Drug: Ifinatamab deruxtecan — also filed as I-DXd
- Drug: Topotecan
- Drug: Amrubicin
- Drug: Lurbinectedin
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured From the date of randomization to the date of death due to any cause, up to approximately 3.7 years
Publications
- PMID 41055143 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed